JTE-162

Phase 1Small molecule

JTE-162 is one of 3 small molecule programs targeting Cryopyrin-Associated Periodic Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cryopyrin-Associated Periodic SyndromeRecruiting

Cryopyrin-Associated Periodic SyndromePhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Cryopyrin-Associated Periodic Syndrome

#DrugCompanyPhaseTrials

Kineret

SSwedish Orphan Biovitrum

JTE-162

1 3

ARCALYST

Regeneron

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Cryopyrin-Associated Periodic Syndrome

NCT07247266

Clinical

Trials by Indication[1]

Cryopyrin-Associated Periodic Syndrome1 trial

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Recruiting·AAkros Pharma Inc.·Phase 1·NCT07247266·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JTE-162. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JTE-162 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JTE-162. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akros Pharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAkros Pharma Inc.

JTE-162

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cryopyrin-Associated Periodic Syndrome1 trial

References

Drug Info

Quick Facts

Related News